Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. - Wikidata - thesis-toulmin - TriplyDB

Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.

Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.

http://www.wikidata.org/entity/Q33812932

about

Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy The Therapeutic Potential of the Ketogenic Diet in Treating Progressive Multiple Sclerosis Molecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease intervention The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases PGC-1α, mitochondrial dysfunction, and Huntington's disease Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin Human-to-mouse prion-like propagation of mutant huntingtin protein.Pathophysiological processes in multiple sclerosis: focus on nuclear factor erythroid-2-related factor 2 and emerging pathways Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling Role of the Keap1/Nrf2 pathway in neurodegenerative diseases.Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease.Dimethylfumarate suppresses adipogenic differentiation in 3T3-L1 preadipocytes through inhibition of STAT3 activity K(ATP) channel opener diazoxide prevents neurodegeneration: a new mechanism of action via antioxidative pathway activation Fumaric acid esters stimulate astrocytic VEGF expression through HIF-1α and Nrf2.Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease.Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis.Fumarate modulates the immune/inflammatory response and rescues nerve cells and neurological function after stroke in rats.Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease.Oxidative Stress and Huntington's Disease: The Good, The Bad, and The Ugly.Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs.The fumaric acid ester BG-12: a new option in MS therapy.The role of the immune system in Huntington's disease.Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects.Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases.A changing treatment landscape for multiple sclerosis: challenges and opportunities.Prospects for neuroprotective therapies in prodromal Huntington's disease.Role of the Nrf2 signaling system in health and disease.Antioxidative defense mechanisms controlled by Nrf2: state-of-the-art and clinical perspectives in neurodegenerative diseases.Effects of ethanolic extract of Fumaria indica L. on rat cognitive dysfunctions The role of modulation of antioxidant enzyme systems in the treatment of neurodegenerative diseases.

P2860

Q26738969-37E28DFD-9702-40FB-BAB5-A10FDDA86AB4 Q26769966-7640E5F6-AD1B-4175-8015-45A68DEF0F1F Q26778356-143C3EFB-136A-4201-B7FE-BF31D8645324 Q26822972-4324B507-7B8C-451A-9EA0-2EBD4940CBC9 Q27001671-CDF56877-A199-473D-8AB8-439FA5E5FEE5 Q27005950-722BEA13-FB33-44CF-89C4-8575064C5A2C Q27312215-AA35C860-C97C-4C51-B541-CB15AA0E6A46 Q27322062-E2546CDB-27BC-44CA-A800-D6B59AD227F3 Q28235168-CE09D2F4-0A54-49D0-AC61-139180AA8DA5 Q28389828-75E3E1B1-5B37-4860-8038-22240CC144CA Q28391475-4B6962AF-0230-451A-BBF2-99EBB7E35526 Q28396785-A520253A-C2C3-41DE-8144-AF3578CF5101 Q34389325-BA47C3EF-FFB6-433C-B32D-FC57AC2D6550 Q34441024-A0DE9B0B-FFFC-4FF0-AD79-1029E07455A1 Q34464138-8196E71A-FA2E-4489-9CD0-D85D16437E61 Q34581918-CCD89E21-096B-4AE4-BA97-CEC4AC8CE6A7 Q34700280-2C5D6AE0-30DA-4E50-AF2D-BBE0F7A83D1F Q34990563-EB618540-BCD6-48B9-BBDA-1D3F2454266E Q35009620-75C749D2-6D34-41E4-B397-F72EBB728633 Q35814106-BEA6E0B2-7A2A-4634-8D1E-0A29010DB073 Q36393675-38D88A0A-FB15-40F2-9E33-66E5E7BC1152 Q36732766-9C967FB6-96F5-4F53-BF97-6F2D8DAA25DB Q36985371-4560B49C-606A-487D-A301-D5F83F6C5A79 Q37122279-DE34AEF5-F21F-4AF3-BBE9-1ABF6A5E9908 Q37169655-9F5AC0FF-AF5B-48D3-8387-5AD777B0BFFA Q37221728-64E2505D-741D-4D1C-AD51-F6F2FF17F932 Q37336648-7B872835-8C54-42E4-92F9-E34E5AC2018C Q37607467-9F7CCB77-32F2-4F03-9A96-8F7A6A7F1F8E Q37643688-E96F753E-570F-4385-8DC7-470BBE7F9D9E Q38124678-D58F9024-62B3-4BCD-ADD5-10894C0254C9 Q38128863-56C751A7-9F27-4D5E-A017-5C60659E8A20 Q38129870-9C47C7E1-1A45-46A2-B822-66AD3248F97F Q38141840-E0156F98-EB06-46E1-9175-94F84CFCF109 Q38167610-6F2C8277-1C62-4017-839D-C9F930333D3F Q38180166-3792EA9A-8EF2-4271-91DE-BC388B03A542 Q38191477-17AC7371-BBBD-465A-B8CC-D54C77C61282 Q38237494-57CE7D9B-EC48-4827-9B36-91F805ED121D Q38244092-F3FECA63-05E8-4D07-AA28-C04A076D22C8 Q38546625-C8632160-44B4-4E9E-B413-08BD5A96E48D Q38889475-EBB47D93-696F-4566-B8CA-8A18780F8429

P2860

Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.

http://www.wikidata.org/entity/Q33812932

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.

@ast

Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.

@en

type

label

Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.

@ast

Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.

@en

prefLabel

Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.

@ast

Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.

@en

P1433

Q33812932-1619F69A-38EA-4E60-8C54-77D44FFA8D3F

P1476

Q33812932-66393A3E-D07C-42F9-A69A-88966D8700FD

P2093

Q33812932-669BFEDA-E4C3-437E-8A3E-3C6F7084A2A0

Q33812932-7A0D6D4D-7F53-43E3-9403-15058774A33E

Q33812932-7CBDD3EC-DED5-4DD0-BEEC-61A7EF0FCE75

Q33812932-7E8A3884-4A5D-408F-97E3-F31AC0D24FBD

Q33812932-C44B0935-1AF9-49CA-9E06-5B2B86A09D96

Q33812932-E139680B-4884-43A8-952A-36550AB5C9BE

P2860

Q33812932-04D81F94-D7C3-4451-B13D-4926267225BE

Q33812932-05058CCD-62F8-4A1F-800C-A3C688DCBF1F

Q33812932-060ABFF6-3EFB-4796-91EE-C30A3E3665AE

Q33812932-09BA6D51-314E-4C9C-BD0B-78417129AC61

Q33812932-0ADBA685-E059-44BD-AD39-290599322B2A

Q33812932-10F14913-2958-438C-8DF7-5A3ABB2780B5

Q33812932-12D207E3-BD8E-4C11-8496-2180218B8D3C

Q33812932-15F597AA-7BE3-40E4-865A-0680DC235A50

Q33812932-19FA6131-A874-4B82-AC23-1C0BADB9A7B9

Q33812932-255DC4D5-A8D5-4CDC-ADF8-BE5A00991B74

P304

Q33812932-0D52CD88-6101-4F16-909E-B17988C04571

P31

Q33812932-CEE749E0-4900-4CB5-8694-FBB10AD7D5C2

P356

Q33812932-EB6EE1CC-CF3E-429A-83C7-32F90976680F

P407

Q33812932-1436A636-5BFB-4DEE-8FC6-D8F8BC1E168F

P433

Q33812932-1CBA007E-11E2-46D0-94B5-FA6FB417AE7E

P478

Q33812932-38A58955-1C73-4B5F-8661-F7A60C252931

P50

Q33812932-65DC5DA3-A305-49AE-AA25-E53829707081

Q33812932-FBFA3F9D-E281-470E-8A22-199C0DDF0A66

P577

Q33812932-F11C0D7A-8E52-4E8F-9BA6-3BD08F01FAC7

P5875

Q33812932-6A8C08D1-8E4F-4475-80DC-1FD93C208A96

P698

Q33812932-9F5B24CF-BB71-477F-A520-BCE36E0B3576

P921

Q33812932-4D39B9B6-1CC6-445C-806F-CB73E22F3D97

P932

Q33812932-9980CD49-8E76-4689-97E4-78F014EF05C3

P356

JOURNAL.PONE.0016172

P1433

P1476

Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.

@en

P2093

Christiane Reick

http://www.w3.org/2001/XMLSchema#string

De-Hyung Lee

http://www.w3.org/2001/XMLSchema#string

Gisa Ellrichmann

http://www.w3.org/2001/XMLSchema#string

Larissa Arning

http://www.w3.org/2001/XMLSchema#string

Ralf A Linker

http://www.w3.org/2001/XMLSchema#string

Ralf Gold

http://www.w3.org/2001/XMLSchema#string

P2860

Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract

Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice

Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline

Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models.

Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease

Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription.

P304

e16172

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0016172

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Elisabeth Petrasch-Parwez

P577

2011-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49814225

http://www.w3.org/2001/XMLSchema#string

P698

21297955

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

3031519

http://www.w3.org/2001/XMLSchema#string